Canada Markets closed

GlaxoSmithKline plc (GSK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
39.46+0.29 (+0.74%)
At close: 4:00PM EDT
39.55 +0.09 (+0.23%)
After hours: 06:51PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close39.17
Open39.25
Bid39.35 x 3000
Ask39.55 x 2900
Day's Range39.16 - 39.54
52 Week Range33.26 - 42.68
Volume3,448,793
Avg. Volume3,758,441
Market Cap99.271B
Beta (5Y Monthly)0.40
PE Ratio (TTM)13.57
EPS (TTM)2.91
Earnings DateFeb. 01, 2017 - Feb. 06, 2017
Forward Dividend & Yield2.17 (5.41%)
Ex-Dividend DateMay 20, 2021
1y Target Est48.04
  • Editor's Pick
    Yahoo Finance Video

    Doctor on Covid-19: ‘This is a virus that is really here to stay’

    Dr. Elizabeth Clayborne, Adjunct Assistant Professor of Emergency Medicine at the University of Maryland School of Medicine and Emergency Physician at UM Capital Region Medical Center, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.

  • Motley Fool

    Johnson & Johnson May Not Have to Wait Long for Its Next Blockbuster Vaccine

    While Pfizer and BioNTech's Comirnaty and Moderna's COVID-19 vaccine have dominated the discussion surrounding COVID-19 vaccines, Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine has also positioned itself for blockbuster status. For instance, Johnson & Johnson's COVID-19 vaccine is expected to bring in $2.5 billion for the pharma stock this year alone. Let's discuss the clinical results of Johnson & Johnson's RSV vaccine candidate to date, as well as its sales potential to understand why this could be Johnson & Johnson's next blockbuster vaccine.

  • Motley Fool

    Can Pfizer and GlaxoSmithKline Beat Johnson & Johnson's RSV Vaccine?

    Johnson & Johnson (NYSE: JNJ) recently announced positive results from a phase 2 study of its RSV vaccine candidate. In this Motley Fool Live video recorded on Oct. 6, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not J&J set a high bar for Pfizer (NYSE: PFE) and GlaxoSmithKline (NYSE: GSK) to top.